Targeted excision of VCP R155H mutation by Cre-LoxP technology as a promising therapeutic strategy for valosin-containing protein disease

Human Gene Therapy Methods

Volumn 26, Issue 1, 2015, Pages 13-24

  Nalbandian, Angèle ^a   Llewellyn, Katrina J ^a   Nguyen, Christopher ^a   Monuki, Edward S ^b   Kimonis, Virginia E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORN OIL; CRE RECOMBINASE; TAMOXIFEN; VALOSIN CONTAINING PROTEIN; INTEGRASE; PEPTIDE; VALOSIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CELL INCLUSION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; FEMALE; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION; GENE MUTATION; HEART FAILURE; IMMUNOHISTOCHEMISTRY; INCLUSION BODY MYOPATHY; LOXP SITE; MARE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOPATHY; NONHUMAN; OPEN READING FRAME; PAGET BONE DISEASE; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; RESPIRATORY FAILURE; ANIMAL; APOPTOSIS; BRAIN; GENE TARGETING; GENE THERAPY; GENETICS; METABOLISM; MISSENSE MUTATION; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MYOSITIS, INCLUSION BODY; OSTEITIS DEFORMANS; PATHOLOGY; PROCEDURES; SKELETAL MUSCLE;

MUS; ZEA MAYS;

ANIMALS; APOPTOSIS; AUTOPHAGY; BRAIN; FRONTOTEMPORAL DEMENTIA; GENE TARGETING; GENETIC THERAPY; INTEGRASES; MICE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUTATION, MISSENSE; MYOSITIS, INCLUSION BODY; OSTEITIS DEFORMANS; PEPTIDES;

EID: 84923260646     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2014.096     Document Type: Article

References (44)

1. Kimonis VE, et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet Med 2000; 2: 232-241
2. Kovach MJ, et al. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab 2001; 74: 458-475
3. Watts GD, et al. Clinical and genetic heterogeneity in chromosome 9p associated hereditary inclusion body myopathy: exclusion of GNE and three other candidate genes. Neuromuscul Disord 2003; 13: 559-567
4. Watts GD, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36: 377-381
5. Kimonis VE, et al. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A 2008; 146: 745-757
6. Kimonis VE, et al. VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim Biophys Acta 2008; 1782: 744-748
7. Kimonis VE, Watts GD. Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer Dis Assoc Disord 2005; 19: S44-S47
8. Kimonis V, et al. Inclusion body myopathy associated with paget disease of bone and/or frontotemporal dementia gene. Muscle Nerve 2011. doi: 10.1002/mus.23960
9. Schroder R, et al. Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann Neurol 2005; 57: 457-461
10. Djamshidian A, et al. A novel mutation in the VCP gene (G157R) in a German family with inclusion-body myopathy with Paget disease of bone and frontotemporal dementia. Muscle Nerve 2009; 39: 389-391
11. Guyant-Marechal L, et al. Valosin-containing protein gene mutations: clinical and neuropathologic features. Neurology 2006; 67: 644-651
12. Haubenberger D, et al. Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology 2005; 65: 1304-1305
13. Bersano A, et al. Inclusion body myopathy and frontotemporal dementia caused by a novel VCP mutation. Neurobiol Aging 2007; 30: 752-758
14. Viassolo V, et al. Inclusion body myopathy, Paget's disease of the bone and frontotemporal dementia: recurrence of the VCP R155H mutation in an Italian family and implications for genetic counselling. Clin Genet 2008; 74: 54-60
15. Miller TD, et al. Inclusion body myopathy with Paget disease and frontotemporal dementia (IBMPFD): clinical features including sphincter disturbance in a large pedigree. J Neurol Neurosurg Psychiatry 2009; 80: 583-584
16. Kumar KR, et al. Two Australian families with inclusionbody myopathy, Paget's disease of bone and frontotemporal dementia: novel clinical and genetic findings. Neuromuscul Disord 2010; 20: 330-334
17. Fanganiello RD, et al. A Brazilian family with IBMPFD caused by p.R93C mutation in the VCP gene and literature review for genotype-phenotype correlations. Exp Brain Res 2011; 44: 374-380
18. Kim EJ, et al. Inclusion body myopathy with Paget disease of bone and frontotemporal dementia linked to VCP p.Arg155Cys in a Korean family. Arch Neurol 2011; 68: 787-796
19. Komatsu J, et al. Inclusion body myopathy with Paget disease of the bone and frontotemporal dementia associated with a novel G156S mutation in the VCP gene. Muscle Nerve 2013. [Epub ahead of print]; doi: 10.1002/mus.23960
20. Watts GD, et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet 2007; 72: 420-426
21. Spina S, et al. Frontotemporal dementia associated with a valosin-containing protein mutation: report of three families. FASEB J 2008; 22: 58.4
22. Johnson JO, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68: 857-864
23. Kim NC, et al. VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations. Neuron 2013; 78: 65-80
24. De La Barre B, et al. Central pore residues mediate the p97/VCP activity required for ERAD. Mol Cell 2006; 22: 451-462
25. Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci 2010; 13: 805-811
26. Komatsu M, et al. Autophagy and neurodegeneration. Autophagy 2006; 2: 315-317
27. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42
28. Malicdan MC, Nishino I. Autophagy in lysosomal myopathies. Brain Pathol 2012; 22: 82-88
29. Tung YT, et al. Autophagy: a double-edged sword in Alzheimer's disease. J Biosci 2012; 37: 157-165
30. Kemaladewi DU, et al. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics 2011; 4: 36
31. Pichavant C, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 2011; 19: 830-840
32. Shi S, et al. Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva. PLoS One 2013; 8: e69096
33. Badadani M, et al. VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PLoS One 2010; 5: e13183
34. Zhang W, et al. Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. Neurosurgery 1996; 38: 587-590; discussion 590-591
35. Furukawa S, et al. The impairment of metrial gland development in tamoxifen exposed rats. Exp Toxicol Pathol 2012; 64: 121-126
36. Verrou C, et al. Comparison of the tamoxifen regulated chimeric Cre recombinases MerCreMer and CreMer. Biol Chem 1999; 380: 1435-1438
37. Nalbandian A, et al. A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/.+ ) mouse. Muscle Nerve 2013; 47: 260-270
38. Vesa J, et al. Valosin containing protein associated inclusion body myopathy: abnormal vacuolization, autophagy and cell fusion in myoblasts. Neuromuscul Disord 2009; 19: 766-772
39. de Medina P, et al. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 2009; 5: 1066-1067
40. Kudoh H, et al. A new model mouse for Duchenne muscular dystrophy produced by 2.4Mb deletion of dystrophin gene using Cre-loxP recombination system. Biochem Biophys Res Commun 2005; 328: 507-516
41. Aoki Y, et al. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA 2012; 109: 13763-13768
42. Malerba A, et al. Dual myostatin and dystrophin exon skipping by morpholino nucleic acid oligomers conjugated to a cell-penetrating peptide is a promising therapeutic strategy for the treatment of duchenne muscular dystrophy. Mol Ther Nucleic Acids 2012; 1: e62
43. Yang L, et al. Effective exon skipping and dystrophin restoration by 2¢-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice. PLoS One 2013; 8: e61584
44. Wu B, et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 2008; 105: 14814-14819